Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc.verified

RXDX

Price:

$199.92

Market Cap:

$9.56B

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated disea...[Read more]

Industry

Biotechnology

IPO Date

2021-03-12

Stock Exchange

NASDAQ

Ticker

RXDX

The PE Ratio as of April 2024 (TTM) for Prometheus Biosciences, Inc. (RXDX) is -56.47

According to Prometheus Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -56.47. This represents a change of 160.41% compared to the average of -21.69 of the last 4 quarters.

Prometheus Biosciences, Inc. (RXDX) Historical PE Ratio (quarterly & annually)

How has RXDX PE Ratio performed in the past?

The mean historical PE Ratio of Prometheus Biosciences, Inc. over the last ten years is -16.90. The current -56.47 PE Ratio has changed 33.32% with respect to the historical average. Over the past ten years (40 quarters), RXDX's PE Ratio was at its highest in in the March 2021 quarter at -2.73. The PE Ratio was at its lowest in in the March 2023 quarter at -31.15.

Quarterly (TTM)
Annual

Average

-16.90

Median

-13.78

Minimum

-31.52

Maximum

-7.35

Prometheus Biosciences, Inc. (RXDX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Prometheus Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 138.35%

Maximum Annual PE Ratio = -7.35

Minimum Annual Increase = -38.22%

Minimum Annual PE Ratio = -31.52

Quarterly (TTM)
Annual
YearPE RatioChange
2022-31.52128.80%
2021-13.78-38.22%
2020-22.30-0.37%
2019-22.38138.35%
2016-9.3927.83%
2015-7.35-36.63%

Prometheus Biosciences, Inc. (RXDX) Average PE Ratio

How has RXDX PE Ratio performed in the past?

The current PE Ratio of Prometheus Biosciences, Inc. (RXDX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-22.53

5-year avg

-19.87

10-year avg

-16.90

Prometheus Biosciences, Inc. (RXDX) PE Ratio vs. Peers

How is RXDX’s PE Ratio compared to its peers?

Prometheus Biosciences, Inc.’s PE Ratio is less than Apellis Pharmaceuticals, Inc. (-11.05), less than Akero Therapeutics, Inc. (-7.04), less than Immunovant, Inc. (-16.56), less than Madrigal Pharmaceuticals, Inc. (-10.29), less than Roivant Sciences Ltd. (1.97), less than Krystal Biotech, Inc. (400.66), less than 89bio, Inc. (-3.30), less than Pliant Therapeutics, Inc. (-4.46), less than Arcellx, Inc. (-37.14), less than Stoke Therapeutics, Inc. (-4.98), greater than Viking Therapeutics, Inc. (-73.76), less than Intercept Pharmaceuticals, Inc. (-13.55), less than Terns Pharmaceuticals, Inc. (-3.61), greater than Reata Pharmaceuticals, Inc. (-89.36), less than IVERIC bio, Inc. (-33.43), less than Blueprint Medicines Corporation (-10.71), less than Amylyx Pharmaceuticals, Inc. (2.50), less than Karuna Therapeutics, Inc. (-29.52), less than Day One Biopharmaceuticals, Inc. (-6.48),

Build a custom stock screener for Prometheus Biosciences, Inc. (RXDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prometheus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prometheus Biosciences, Inc. (RXDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prometheus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Prometheus Biosciences, Inc.'s PE Ratio?

How is the PE Ratio calculated for Prometheus Biosciences, Inc. (RXDX)?

What is the highest PE Ratio for Prometheus Biosciences, Inc. (RXDX)?

What is the 3-year average PE Ratio for Prometheus Biosciences, Inc. (RXDX)?

What is the 5-year average PE Ratio for Prometheus Biosciences, Inc. (RXDX)?

How does the current PE Ratio for Prometheus Biosciences, Inc. (RXDX) compare to its historical average?